Drugs / MEDI9090
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02900157 | Aug 2016 → Jan 2020 | cancer | MedImmune LLC | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MEDI9090 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02900157 ↗ |
| Route | Intravenous | “MEDI9090 will be administered by IV infusion” NCT02900157 ↗ |